Indonesia unexpectedly limits omega-3 supplement claims

By Gary Scattergood

- Last updated on GMT

Indonesia has issued restrictions on omega-3 supplement claims. ©iStock
Indonesia has issued restrictions on omega-3 supplement claims. ©iStock
Badan Pom (BPOM), the National Agency of Drug and Food Control of Indonesia, has unexpectedly limited supplement claims for EPA and DHA.

A recent circular states health claims for DHA and EPA are only permitted under 300mg/day. 

It also said health Supplements containing DHA/EPA must list the warning that consumers should “be careful when consuming products which contain more ΕΡΑ than DHA in conjunction with anti-coagulants, because they may increase the blood thinning effect.”

They must also state “If you are going to have surgery, communicate with doctors regarding the use of these supplements.”

Under the new edict, health supplements containing more than 300mg/day are not able to use claims for health maintenance.

Global omega-3 trade body GOED is now compiling information to submit to BPOM for its review.

The organisation's VP of Regulatory Harry Rice told us it was not clear what provoked BPOM’s reaction and that there was no indication the change was on the cards. 

“As far as we know, before this circular, there was no daily limit for EPA and DHA. Even when BPOM talked about putting certain restrictions on the sale of omega-3 rich oils a number of years ago, there was no daily limit discussed. 

“Members are eager to see this issue resolved, not only because of its restriction on the Indonesian market, but because it could have an impact on what other countries decide to do,” ​he added.

The BPOM circular also adds that information about the content of DHA can only be included in part of the composition/nutritional value information on the label and that “health supplements with DHA/EPA which have had a marketing authorization shall adjust at the latest two (2) years from the date of this Circular."

GOED says it has successfully worked with BPOM on resolving issues restricting the sale of EPA/DHA-rich oils in the past and pledged to keep members updated on its progress.

Related news

Show more

Related products

show more

Research for Restorative Sleep: Levagen®+

Research for Restorative Sleep: Levagen®+

Content provided by Gencor | 27-Sep-2024 | White Paper

Levagen®+ is Gencor's branded Palmitoylethanolamide (PEA), an endogenous fatty acid amide naturally found in every cell of the body.

Harness the power of algae for omega-3 innovation

Harness the power of algae for omega-3 innovation

Content provided by dsm-firmenich | 08-May-2024 | Insight Guide

Algal-sourced omega-3s have limitless potential, able to scale to meet the needs of our planet’s population with twice the potency – naturally – and all...

Nootropics Report 2.0: Brain Health Insights

Nootropics Report 2.0: Brain Health Insights

Content provided by dsm-firmenich | 22-Feb-2024 | Insight Guide

The brain health market is constantly growing and evolving, with more consumers looking for innovative ways to support total mind and body wellness.

Pycnogenol® Supports Cognitive Function at Any Age

Pycnogenol® Supports Cognitive Function at Any Age

Content provided by Horphag Research | 07-Feb-2024 | White Paper

Clinical research shows daily supplementation with Pycnogenol® French maritime pine bark extract may help support brain function in a variety of age groups...

Related suppliers

Follow us

Products

View more

Webinars

Nutra Champions Podcast